OTHER ASIA

Other Asia comprises all Asian territories excluding China and Japan. Anaesthetics make up 36% of revenue in these countries and territories, followed by several products in the Other Commercial Pharmaceutical brands category. We have active trading subsidiaries in the Philippines, Taiwan and Malaysia.

Key Countries and Territories

Hong Kong
Indonesia
Philippines
Taiwan

Contribution to Group revenue

Revenue contribution - by therapeutic category

The Philippines pharmaceutical sector grew 6,9% and was valued at USD3,4 billion as at 30 June 2017.
The Taiwan pharmaceutical sector grew 0,5% and was valued at USD5,4 billion as at 30 June 2017.
The Indonesian pharmaceutical sector grew 0,3% and was valued at USD3,6 billion as at 30 June 2017.

Source: June 2017 IMS

STATISTICS

Number of products launched:

3

(2016: 8)

IMS value of pipeline as at 30 June 2017 anticipated to be launched in:

0 – 2 years

USD49 million

3 – 5 years

USD12 million

Number of product recalls:

Nil

(2016: nil)

Average staff turnover:

26,0%

(2016: 31,7%)

Number of work-related fatalities:

Nil

(2016: nil)

Number of permanent employees:

Revenue – R’billion	2017	2016 (CER)*	% change
Total	1,2	0,9	50
Anaesthetics	0,4	–	>100
Thrombosis	0,2	0,2	4
High Potency & Cytotoxics	0,3	0,3	(3)
Other Commercial Pharmaceutical Brands	0,3	0,4	(7)

* Constant exchange rate: FY16 restated at FY17 average exchange rates.
Note: Commercial Pharmaceuticals revenue by customer geography and manufacturing revenue by place of manufacture.